Monoclonal antibody therapy in sinonasal disease

Sergio E. Chiarella; Hendrik Sy; Anju T. Peters

doi:10.2500/ajra.2017.31.4412

Monoclonal antibody therapy in sinonasal disease

Sergio E. Chiarella, Hendrik Sy, Anju T. Peters^*

^*Corresponding author for this work

Medicine, Allergy Division

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Abstract

Chronic rhinosinusitis (CRS) affects 12.5% of the U.S. population. CRS can be divided into CRS with nasal polyps (CRSwNP) and CRS without nasal polyps. Some individuals with CRSwNP do not respond to standard-of-care medical and surgical management. For these individuals, targeted biologic agents are emerging as an important therapeutic alternative. In this review, we described the most-relevant studies that addressed the use of anti-immunoglobulin E (omalizumab), anti-interleukin 5 (mepolizumab and reslizumab), and anti-interleukin 4/interleukin 13 (dupilumab) monoclonal antibodies for the treatment of CRSwNP. In addition, we discussed the importance of some of these clinical trials in identifying new CRS endotypes based on distinct inflammatory profiles.

Original language	English (US)
Pages (from-to)	93-95
Number of pages	3
Journal	American Journal of Rhinology and Allergy
Volume	31
Issue number	2
DOIs	https://doi.org/10.2500/ajra.2017.31.4412
State	Published - Mar 1 2017

ASJC Scopus subject areas

Immunology and Allergy
Otorhinolaryngology

Access to Document

10.2500/ajra.2017.31.4412

Cite this

@article{65b832e13fbc458a82d12b564d3d00eb,

title = "Monoclonal antibody therapy in sinonasal disease",

abstract = "Chronic rhinosinusitis (CRS) affects 12.5% of the U.S. population. CRS can be divided into CRS with nasal polyps (CRSwNP) and CRS without nasal polyps. Some individuals with CRSwNP do not respond to standard-of-care medical and surgical management. For these individuals, targeted biologic agents are emerging as an important therapeutic alternative. In this review, we described the most-relevant studies that addressed the use of anti-immunoglobulin E (omalizumab), anti-interleukin 5 (mepolizumab and reslizumab), and anti-interleukin 4/interleukin 13 (dupilumab) monoclonal antibodies for the treatment of CRSwNP. In addition, we discussed the importance of some of these clinical trials in identifying new CRS endotypes based on distinct inflammatory profiles.",

author = "Chiarella, {Sergio E.} and Hendrik Sy and Peters, {Anju T.}",

year = "2017",

month = mar,

day = "1",

doi = "10.2500/ajra.2017.31.4412",

language = "English (US)",

volume = "31",

pages = "93--95",

journal = "American Journal of Rhinology and Allergy",

issn = "1945-8924",

publisher = "OceanSide Publications Inc.",

number = "2",

}

TY - JOUR

T1 - Monoclonal antibody therapy in sinonasal disease

AU - Chiarella, Sergio E.

AU - Sy, Hendrik

AU - Peters, Anju T.

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Chronic rhinosinusitis (CRS) affects 12.5% of the U.S. population. CRS can be divided into CRS with nasal polyps (CRSwNP) and CRS without nasal polyps. Some individuals with CRSwNP do not respond to standard-of-care medical and surgical management. For these individuals, targeted biologic agents are emerging as an important therapeutic alternative. In this review, we described the most-relevant studies that addressed the use of anti-immunoglobulin E (omalizumab), anti-interleukin 5 (mepolizumab and reslizumab), and anti-interleukin 4/interleukin 13 (dupilumab) monoclonal antibodies for the treatment of CRSwNP. In addition, we discussed the importance of some of these clinical trials in identifying new CRS endotypes based on distinct inflammatory profiles.

AB - Chronic rhinosinusitis (CRS) affects 12.5% of the U.S. population. CRS can be divided into CRS with nasal polyps (CRSwNP) and CRS without nasal polyps. Some individuals with CRSwNP do not respond to standard-of-care medical and surgical management. For these individuals, targeted biologic agents are emerging as an important therapeutic alternative. In this review, we described the most-relevant studies that addressed the use of anti-immunoglobulin E (omalizumab), anti-interleukin 5 (mepolizumab and reslizumab), and anti-interleukin 4/interleukin 13 (dupilumab) monoclonal antibodies for the treatment of CRSwNP. In addition, we discussed the importance of some of these clinical trials in identifying new CRS endotypes based on distinct inflammatory profiles.

UR - http://www.scopus.com/inward/record.url?scp=85015759888&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015759888&partnerID=8YFLogxK

U2 - 10.2500/ajra.2017.31.4412

DO - 10.2500/ajra.2017.31.4412

M3 - Article

C2 - 28281440

AN - SCOPUS:85015759888

SN - 1945-8924

VL - 31

SP - 93

EP - 95

JO - American Journal of Rhinology and Allergy

JF - American Journal of Rhinology and Allergy

IS - 2

ER -

Monoclonal antibody therapy in sinonasal disease

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this